The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain

INTRODUCTION: Once-weekly semaglutide has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight than sitagliptin and dulaglutide in the SUSTAIN 2 and 7 clinical trials, respectively. These trials also assessed the proportions of patients achieving treatment targets c...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidal, Josep, Malkin, Samuel J. P., Hunt, Barnaby, Martín, Virginia, Hallén, Nino, Javier Ortega, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995797/
https://www.ncbi.nlm.nih.gov/pubmed/31925724
http://dx.doi.org/10.1007/s13300-019-00751-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995797/
https://www.ncbi.nlm.nih.gov/pubmed/31925724
http://dx.doi.org/10.1007/s13300-019-00751-7

Ejemplares similares